MedTrace Logo

Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

NCT00530595 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2007-09-17

No results posted yet for this study

Summary

Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Conditions

Interventions

DRUG

candesartan or valsartan or losartan

Sponsors & Collaborators

  • Saitama Medical University

    lead OTHER

Principal Investigators

  • Hiromichi Suzuki, MD, PhD · Department of Nephrology, Saitama Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00530595 on ClinicalTrials.gov